Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

19.9%

36 terminated/withdrawn out of 181 trials

Success Rate

75.5%

-11.1% vs industry average

Late-Stage Pipeline

2%

4 trials in Phase 3/4

Results Transparency

56%

62 of 111 completed trials have results

Key Signals

16 recruiting62 with results23 terminated13 withdrawn

Enrollment Performance

Analytics

Phase 2
75(44.9%)
Phase 1
48(28.7%)
N/A
39(23.4%)
Phase 3
4(2.4%)
Early Phase 1
1(0.6%)
167Total
Phase 2(75)
Phase 1(48)
N/A(39)
Phase 3(4)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (181)

Showing 20 of 181 trials
NCT07796126Phase 2Not Yet Recruiting

Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status

Role: lead

NCT07743086Phase 1Not Yet Recruiting

Impact of Duffy-null Associated Neutropenia on Chemotherapy Dosing

Role: lead

NCT07227831Not ApplicableRecruiting

A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer

Role: lead

NCT00935090Active Not Recruiting

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Role: lead

NCT06576115Phase 2Recruiting

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

Role: lead

NCT07343297Not ApplicableRecruiting

Ask Questions About Clinical Trials

Role: lead

NCT07222306Enrolling By Invitation

Cannabis, Neuroinflammation, and Suicidal Ideation: A Supplemental Brain Imaging Study

Role: collaborator

NCT07042191Not ApplicableActive Not Recruiting

A Provider Intervention to Reduce Financial Toxicity in Patients With Cancer Through Improved Treatment Cost Discussions

Role: lead

NCT03091257Phase 1Active Not Recruiting

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

Role: collaborator

NCT07735819Phase 2Not Yet Recruiting

Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma

Role: lead

NCT02178163Not ApplicableActive Not Recruiting

Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer

Role: lead

NCT07098299Phase 1Recruiting

Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies

Role: lead

NCT01888198Active Not Recruiting

Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment

Role: collaborator

NCT07672431Not ApplicableNot Yet Recruiting

Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression

Role: lead

NCT06420167Phase 2Recruiting

DapagliFLOzin in Renal AL Amyloidosis (FLORAL)

Role: lead

NCT06107738Phase 2Recruiting

Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

Role: lead

NCT05738005Not ApplicableRecruiting

Dietary Reporting In The Amyloidoses

Role: lead

NCT07436078Not ApplicableRecruiting

Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors

Role: lead

NCT05903092Phase 2Recruiting

MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

Role: collaborator

NCT07218432Not ApplicableRecruiting

A Study of the TheraBionic P1 Device in Breast Cancer

Role: lead